编号：2021-05 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-01 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-06 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-07 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 投资者关系活动 类别 ■其他 （投资者电话交流会） 参与单位名称及 人员姓名 兴业证券（胡储辉、孙媛媛）；招商证券（许菲菲、余行）；兴证基 金（李源海、谢治宇、乔迁、陈锦泉、戴心）；中金公司（刘锡源）； 明亚基金（阮帅）；农银理财（申羽峰）；东吴证券（徐梓煜）；Platina Capital（刘文生）；中泰证券（祝嘉琦、李建）；中信资管（魏巍）； 华安（裘倩倩）；浙商证券（毛雅婷、盖文化、孙建）；方正证券（高 睿婷、唐爱金）；民生医药（孙怡）；拾贝投资（陈问）；中信证券 （王凯旋、朱家成、韩世通）；鹏扬基金（王雪刚）；开源证券（余 汝意）；远信资本（叶铮）；国信证券（彭思宇）；中信建投基金（吴 县名）；长盛基金（蓝仝）；华创证券（张泉）；国金证券（王班、 宋阳）；磐行资本（董阳）；Value Partners（李博艺）；东吴人寿（姜 辉）；泓澄投资（金善玉）；招商自营（胡玮凯）；歌斐资产（沈芃 泽）；中泰资管（周旭驰）；东兴自营（经舒扬）；兴华基金（徐迅）； 慎知资产（王宇美、余海丰）；鹤禧投资（Li ...

Financial Performance - The company's revenue for Q3 2022 reached ¥2,565,126,389.01, representing a year-over-year increase of 20.88%[3] - Net profit attributable to shareholders for Q3 2022 was ¥220,292,993.64, up 5.54% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥244,796,455.99, showing a significant increase of 44.21% year-over-year[3] - Total operating revenue for Q3 2022 reached ¥7,550,804,383.47, an increase of 17.98% compared to ¥6,399,153,386.70 in the same period last year[13] - Net profit for Q3 2022 was ¥657,091,282.69, a decrease of 13.81% from ¥762,133,599.43 in Q3 2021[14] - Total profit for Q3 2022 was ¥765,962,199.28, down 14.85% from ¥899,545,208.98 in the same quarter last year[14] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,157,718,538.84, reflecting a growth of 21.76% from the end of the previous year[3] - As of September 30, 2022, the total assets of the company reached CNY 11.16 billion, an increase from CNY 9.16 billion at the beginning of the year, representing a growth of approximately 21.8%[11] - The company's total liabilities increased, with short-term borrowings rising by 69.18% to ¥562,490,104.30 compared to the previous year[6] - The total liabilities of the company were CNY 5.97 billion, compared to CNY 4.10 billion at the beginning of the year, marking an increase of around 45.5%[12] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥870,772,728.39, an increase of 31.74% compared to the same period last year[6] - Cash inflow from operating activities totaled ¥6,008,821,887.45, an increase of 19.5% from ¥5,029,206,843.86 year-on-year[15] - The net increase in cash and cash equivalents for the quarter was ¥357,478,983.53, compared to ¥49,549,859.45 in the same quarter last year[16] - The ending balance of cash and cash equivalents reached ¥2,156,631,616.93, up from ¥1,973,988,633.38 at the end of the previous period[16] Research and Development - Research and development expenses for the first nine months of 2022 were ¥405,006,874.25, which is a 25.98% increase year-over-year[6] - Research and development expenses rose to ¥405,006,874.25, representing a 25.94% increase from ¥321,495,631.04 in the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,851, with the largest shareholder holding 28.08% of the shares[7] Operational Efficiency and Future Plans - The company has plans for market expansion and new product development, although specific details were not provided in the report[12] - The report indicates a focus on enhancing operational efficiency and exploring strategic partnerships to drive future growth[12] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 4.24%, a decrease of 0.18% compared to the previous year[3] - Earnings per share (EPS) for Q3 2022 was ¥0.5594, down from ¥0.6467 in Q3 2021, reflecting a decrease of 13.46%[14] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,369,975.63 compared to ¥37,930.80 in the previous year[14]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥4,985,677,994.46, representing a 16.57% increase compared to ¥4,277,125,693.79 in the same period last year[11]. - Net profit attributable to shareholders was ¥436,984,822.35, a decrease of 21.04% from ¥553,408,494.47 in the previous year[11]. - The basic earnings per share decreased by 20.98% to ¥0.3711 from ¥0.4696 in the same period last year[11]. - Total assets increased by 12.77% to ¥10,333,214,784.46 compared to ¥9,163,329,850.05 at the end of the previous year[11]. - The net assets attributable to shareholders decreased by 1.34% to ¥4,992,417,721.43 from ¥5,060,005,493.00 at the end of the previous year[11]. - The company reported a net cash flow from operating activities of ¥328,376,803.05, a slight increase of 1.61% from ¥323,169,178.27 in the previous year[11]. - The weighted average return on equity was 8.59%, down from 12.10% in the same period last year, reflecting a decrease of 3.51%[11]. - The company's operating costs increased by 25.44% to approximately CNY 3.74 billion, primarily due to rising raw material prices and increased freight costs[37]. Revenue Breakdown - The pharmaceutical main business generated ¥4,956,591,096.01, accounting for 99.42% of total revenue, with a year-on-year growth of 16.35%[39]. - Contract research services revenue increased by 27.79% to ¥921,144,358.77, representing 18.48% of total revenue[38]. - Domestic revenue was ¥2,836,934,879.85, a slight increase of 1.95% year-on-year, while international revenue surged by 43.77% to ¥2,148,743,114.61[38]. Research and Development - The company invested CNY 282 million in R&D, a 37.43% increase year-on-year, representing 5.66% of total revenue, with 933 R&D personnel including 45 PhDs and 207 Masters[22]. - The company has 13 products that have passed consistency evaluation, including three new formulations approved in the reporting period[21]. - The company holds a total of 138 valid patents, including 120 invention patents, with 12 new invention patent applications submitted during the reporting period[24]. Operational Efficiency - A total of 18 production lines underwent continuous transformation, and over 40 production lines were automated, significantly improving operational efficiency[26]. - The company completed 4,654 employee suggestions, 159 improvement projects, and 149 innovation projects, enhancing operational efficiency and reducing costs[28]. Environmental and Social Responsibility - The company has implemented ISO14001 and ISO45001 management systems to enhance environmental and occupational health safety standards[48]. - The company has a focus on environmental protection and has established a comprehensive EHS management system[48]. - The company actively engages in social responsibility initiatives, including community support and employee welfare programs[66]. Shareholder and Equity Information - The company plans to repurchase shares with a total fund of 200 million to 400 million yuan, having already repurchased 7,568,216 shares, accounting for 0.64% of the total share capital[31]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, totaling 330,941,729 shares[90]. - The total number of ordinary shareholders at the end of the reporting period was 59,683[90]. Risk Management - The company has identified potential risks in future operations and has outlined corresponding countermeasures in the management discussion section[2]. - The company is actively monitoring foreign exchange rate fluctuations to mitigate potential impacts on revenue from export operations[48]. Compliance and Governance - The company has received multiple certifications, including NMPA, FDA, and EU EDQM, ensuring compliance with international quality standards[34]. - There were no administrative penalties due to environmental issues during the reporting period[63]. - The company has not experienced any major litigation or arbitration matters during the reporting period[68]. Financial Position - Cash and cash equivalents at the end of the reporting period amounted to ¥2,672,534,937.85, accounting for 25.86% of total assets, a decrease of 2.62% from the previous year[40]. - The company reported a total of 205,313,446.13 in tax refunds received during the first half of 2022, compared to 161,923,834.61 in the same period of 2021[108]. - The total actual guarantee amount accounts for 65.66% of the company's net assets[85].

Financial Performance - The company's revenue for Q1 2022 was ¥2,101,428,825.31, representing a 6.85% increase compared to ¥1,966,705,576.05 in the same period last year[2] - Net profit attributable to shareholders decreased by 29.96% to ¥152,091,656.06 from ¥217,157,530.74 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥135,904,532.94, down 28.30% from ¥189,535,650.14 in the previous year[2] - Total operating revenue for the first quarter of 2022 was CNY 2,101,428,825.31, an increase of 6.84% compared to CNY 1,966,705,576.05 in the same period last year[12] - Net profit for the first quarter of 2022 was CNY 152,091,656.06, a decrease of 30.03% from CNY 217,157,530.74 in the previous year[12] - Basic earnings per share for the first quarter of 2022 were CNY 0.1291, down from CNY 0.1843 in the same period last year, a decrease of 30%[14] Cash Flow - Operating cash flow increased by 15.89% to ¥171,696,287.82 compared to ¥148,153,167.43 in the same period last year[2] - The net cash flow from operating activities for Q1 2022 was ¥171,696,287.82, an increase from ¥148,153,167.43 in Q1 2021, representing a growth of approximately 15.4%[16] - Total cash inflow from operating activities amounted to ¥1,512,778,824.01, compared to ¥1,396,429,403.54 in the previous year, indicating an increase of about 8.3%[16] - Cash outflow from operating activities totaled ¥1,341,082,536.19, up from ¥1,248,276,236.11, reflecting a rise of approximately 7.4%[16] - The net cash flow from investing activities was -¥213,369,394.57, worsening from -¥25,016,560.53 year-over-year[16] - The net cash flow from financing activities increased by 78.80% to ¥363,036,069.47 from ¥203,041,368.36 year-on-year[5] - Cash inflow from financing activities reached ¥533,000,000.00, compared to ¥435,000,000.00 in the same quarter last year, marking an increase of about 22.5%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,019,157,968.42, a 9.34% increase from ¥9,163,329,850.05 at the end of the previous year[2] - The total liabilities increased to CNY 4,807,046,042.98 from CNY 4,103,324,357.05, representing a rise of 17.14%[11] - The company's total current assets as of March 31, 2022, amount to ¥6,521,432,245.87, an increase from ¥5,781,909,915.75 at the beginning of the year[9] - Cash and cash equivalents increased to ¥2,988,413,275.38 from ¥2,610,010,623.44[8] - Inventory as of March 31, 2022, is valued at ¥1,356,152,503.90, up from ¥1,249,878,604.74[9] - The company reported short-term borrowings of ¥501,225,701.15, an increase from ¥332,474,393.04[9] - Accounts payable decreased slightly to ¥1,237,962,676.03 from ¥1,300,673,202.35[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 47,191[6] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares[6] - The company has a total of 0 preferred shareholders at the end of the reporting period[7] Research and Development - Research and development expenses increased by 45.30% to ¥142,277,701.47 from ¥97,918,833.44 year-on-year[5] - Research and development expenses increased to CNY 142,277,701.47, compared to CNY 97,918,833.44, marking a year-over-year increase of 45.16%[12] Other Information - The report indicates that there are no significant new strategies or product developments mentioned in the current quarter[8] - The company reported a decrease in tax expenses to CNY 29,796,752.46 from CNY 42,198,139.45, a reduction of 29.36%[12] - Other comprehensive income after tax was CNY 14,776.38, compared to a loss of CNY 54,155.88 in the previous year, indicating a positive turnaround[14] - The company did not conduct an audit for the Q1 2022 report[18]

Financial Performance - The total revenue for 2021 was ¥8,942,618,232.82, representing a 13.49% increase compared to ¥7,879,672,743.47 in 2020[11]. - The net profit attributable to shareholders was ¥955,550,170.21, up 17.00% from ¥816,730,067.12 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was ¥833,083,068.11, reflecting a 20.53% increase from ¥691,196,908.38 in 2020[11]. - The basic earnings per share for 2021 was ¥0.8108, a 17.00% increase compared to ¥0.6930 in 2020[11]. - The total revenue for the first quarter was ¥1,966,705,576.05, with a peak in the fourth quarter at ¥2,543,464,846.12, reflecting a quarterly growth of approximately 29%[14]. - Net profit attributable to shareholders in the second quarter reached ¥336,250,963.73, while the fourth quarter saw a decline to ¥193,416,570.79, indicating a year-over-year decrease of about 43%[14]. - The company achieved a gross profit of CNY 125,327.10 million, with a gross margin of 19.15%[28]. - The CDMO business generated revenue of CNY 139,392.68 million, a year-on-year increase of 32.09%, with a gross profit of CNY 60,108.73 million and a gross margin of CNY 43.12%[28]. - The company's formulation business reported revenue of CNY 86,743.45 million, a 14.11% increase year-on-year, with a gross profit of CNY 49,810.79 million and a gross margin of 57.42%[28]. Assets and Liabilities - The total assets at the end of 2021 amounted to ¥9,163,329,850.05, a 22.26% increase from ¥7,494,787,957.34 at the end of 2020[11]. - The net assets attributable to shareholders were ¥5,060,005,493.00, which is a 15.24% increase from ¥4,390,675,233.32 in 2020[12]. - The company's total liabilities reached ¥4,103,324,357.05, up from ¥3,104,112,724.02, marking a growth of around 32.2%[167]. - The total equity attributable to shareholders increased to ¥5,060,005,493.00 from ¥4,390,675,233.32, showing a rise of about 15.2%[168]. - Accounts receivable amounted to ¥1,446,516,969.93, representing 15.79% of total assets, an increase of 1.33% from the previous year[48]. - The company's total liabilities were ¥363,483,300.68 in 2021, an increase from ¥292,812,732.79 in 2020, reflecting a rise of 24.1%[171]. Cash Flow - The net cash flow from operating activities was ¥611,748,728.68, down 42.26% from ¥1,059,526,132.55 in 2020[11]. - The net cash flow from investment activities dropped significantly by 584.55%, resulting in a net outflow of ¥515,391,145.01 in 2021[46]. - The cash and cash equivalents at the end of the reporting period were ¥2,610,010,623.44, accounting for 28.48% of total assets, a slight decrease of 0.80% from the previous year[48]. - The cash flow from financing activities resulted in a net outflow of approximately ¥204.32 million in 2021, contrasting with a net inflow of approximately ¥78.75 million in 2020[180]. Research and Development - The company invested a total of 479 million CNY in R&D in 2021, representing a year-on-year increase of 34.88% and accounting for 5.36% of total revenue[22]. - The company submitted 14 invention patent applications and received 13 invention patent authorizations during the reporting period, with a total of 131 valid patents by the end of the period[22]. - The company has a total of 879 R&D personnel, including 46 PhDs and 192 Masters, emphasizing its commitment to innovation-driven development[25]. - Research and development expenses increased by 27.47% to 446,219,087.77 CNY in 2021, compared to 350,055,448.09 CNY in 2020[39]. Market and Industry Position - The pharmaceutical manufacturing industry is undergoing significant reforms, with an average price reduction of 53% in selected drugs due to centralized procurement initiatives[19]. - The company has achieved notable rankings, including 40th in the "Top 100 Pharmaceutical Enterprises" by the Ministry of Industry and Information Technology in 2020[21]. - The company has established strategic partnerships with over 30 domestic innovative drug companies to enhance its CDMO business[28]. - The company has a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[25]. Governance and Compliance - The company maintains independence from its controlling shareholders in terms of assets, personnel, and financial operations[62]. - The internal audit department conducted an audit focusing on high-risk areas, providing preventive corrective measures based on findings[60]. - The company emphasizes compliance and governance through its board structure and independent directors[68]. - The company has not faced any major litigation or arbitration matters during the reporting period[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with total COD emissions of 285.19 tons, well below the regulatory limit of 500 mg/L[107]. - The company has implemented a self-inspection and correction process in accordance with the "Special Action Checklist for Listed Company Governance" to enhance governance practices[106]. - The company has invested approximately CNY 37.52 million to enhance wastewater pollution prevention capabilities, ensuring stable and compliant discharge of wastewater[109]. - The company has implemented a "zero direct discharge" transformation for wastewater, actively promoting rainwater and sewage diversion[109]. Shareholder Information - The company plans to distribute a cash dividend of ¥2.85 per 10 shares, based on a total of 1,178,523,492 shares[1]. - The company distributed cash dividends amounting to 35% of the distributable profits in recent years, ensuring shareholder returns[118]. - The total number of shares for the company is 1,178,523,492, with 99.99% being unrestricted shares[139]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, totaling 330,941,729 shares, which are pledged[140].

Financial Performance - The company's revenue for Q3 2021 reached ¥2,122,027,692.91, representing a 16.67% increase year-over-year[2] - Net profit attributable to shareholders was ¥208,725,104.95, up 4.03% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥169,749,985.78, reflecting a 9.82% increase year-over-year[2] - The company reported a 22.45% increase in operating profit, totaling ¥903,070,746.23, driven by higher sales and gross profit[6] - Total operating revenue for Q3 2021 reached CNY 6,399,153,386.70, an increase of 10.1% compared to CNY 5,810,594,633.35 in the same period last year[13] - Net profit attributable to the parent company was CNY 762,133,599.42, up from CNY 630,118,433.62, representing a growth of 20.9% year-over-year[14] - Operating profit for the period was CNY 903,070,746.23, compared to CNY 737,500,990.95 in the previous year, indicating a rise of 22.5%[13] - Total operating costs for the period were CNY 5,585,830,987.06, compared to CNY 5,195,242,655.36, indicating an increase of 7.5%[13] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,786,552,584.33, a 17.24% increase from the previous year[2] - The equity attributable to shareholders increased to ¥4,866,465,554.98, marking a 10.84% rise compared to the end of the previous year[2] - Total liabilities rose to CNY 3,920,087,029.35, up from CNY 3,104,112,724.02, representing a growth of 26.3%[12] - The company's total current assets as of September 30, 2021, amounted to ¥5,827,751,885.92, an increase from ¥4,917,396,988.87 in the previous year[11] - The total non-current assets increased to ¥2,958,800,698.41 from ¥2,577,390,968.47 year-over-year[11] Cash Flow - The operating cash flow for the year-to-date was ¥660,960,893.14, showing a significant decline of 33.83% year-over-year[2] - The net cash flow from operating activities for Q3 2021 was ¥660,960,893.14, a decrease of 33.9% compared to ¥998,942,728.52 in Q3 2020[16] - Total cash inflow from operating activities amounted to ¥5,029,206,843.86, up 12.4% from ¥4,472,455,219.77 in the same period last year[16] - Cash outflow from operating activities increased to ¥4,368,245,950.72, representing a rise of 25.7% compared to ¥3,473,512,491.25 in Q3 2020[16] - The net cash flow from investing activities was -¥452,030,530.24, a significant decline from ¥186,031,436.43 in Q3 2020[16] - Cash inflow from investing activities totaled ¥169,243,259.74, down 70.7% from ¥576,541,842.14 in the previous year[16] - Cash outflow from investing activities increased to ¥621,273,789.98, up 59.1% from ¥390,510,405.71 in Q3 2020[16] - The net cash flow from financing activities was -¥153,091,066.39, compared to -¥26,791,420.46 in Q3 2020[17] - Cash inflow from financing activities reached ¥785,100,000.00, a substantial increase from ¥230,100,000.00 in the same quarter last year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,248[8] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares, with 156,000,000 shares pledged[8] - The company has a total of 32,664,016 shares held under the first employee stock ownership plan[9] Research and Development - Research and development expenses increased by 18.12% to ¥321,495,631.04, indicating a focus on innovation[6] - Research and development expenses increased to CNY 321,495,631.04, up from CNY 272,178,180.32, reflecting a growth of 18.1%[13] Inventory and Accounts Payable - Inventory increased to ¥1,146,406,041.90 from ¥1,086,181,605.07 in the previous year[11] - The company reported a total of ¥1,341,874,527.90 in accounts payable, compared to ¥682,462,979.39 in the previous year[11] Audit Information - The company did not undergo an audit for the Q3 2021 report[18]

Financial Performance - The company's operating revenue for the reporting period was ¥4,277,125,693.79, representing a 7.15% increase compared to ¥3,991,768,060.82 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥553,408,494.47, which is a 28.86% increase from ¥429,471,282.68 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥503,398,008.59, up 25.43% from ¥401,338,011.97 in the same period last year[12]. - The basic earnings per share for the reporting period was ¥0.4696, reflecting a 28.87% increase compared to ¥0.3644 in the previous year[12]. - The total assets at the end of the reporting period were ¥8,435,811,838.42, which is a 12.56% increase from ¥7,494,787,957.34 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥4,657,745,885.88, representing a 6.08% increase from ¥4,390,675,233.32 at the end of the previous year[12]. - The net cash flow from operating activities was ¥323,169,178.27, showing a decrease of 49.90% compared to ¥645,027,102.57 in the same period last year[12]. - The weighted average return on net assets was 12.10%, an increase of 1.23% from 10.87% in the previous year[12]. Business Segments - The CDMO business generated revenue of 720.82 million yuan, up 30.65% year-on-year, with a gross margin of 43.32%, an increase of 2.55 percentage points[17]. - The total number of CDMO clients increased by 51.0% year-on-year, with 355 quoted projects, a 157% increase, and 250 ongoing projects, a 71% increase[17]. - The raw material intermediate business reported revenue of 3.137 billion yuan, a growth of 3.90% year-on-year, with a gross margin of 23.02%[18]. - The formulation business achieved revenue of 402.19 million yuan, a year-on-year increase of 9.46%, with a gross margin of 64.60%, up 10.65 percentage points[19]. Strategic Initiatives - The company is focusing on strategic goals of "refining raw materials, strengthening CDMO, and optimizing formulations" to navigate the complex external environment[17]. - The company is actively expanding its product pipeline, with several new products approved and entering the market, including the injection of cefoperazone[19]. - The company plans to increase its CDMO R&D investment, with a goal of expanding its Shanghai R&D center from 130 to 500 personnel by 2024[24]. - The company is adapting to regulatory changes and increasing environmental standards, which are impacting the pharmaceutical industry[19]. Market Overview - The global pharmaceutical market size is expected to reach $1.45 trillion in 2021 and $1.6395 trillion by 2024, with a compound annual growth rate (CAGR) of 4.4% from 2019 to 2024[20]. - China's pharmaceutical industry has become a major global player, with raw material drug exports accounting for approximately 20% of the global market share[21]. - The CDMO industry in China reached over 40 billion yuan in 2019, growing at approximately 19%, significantly outpacing the global CDMO market growth rate of about 13%[23]. Research and Development - The company has completed 4 domestic formulation registrations and 2 API registrations during the reporting period, along with 7 new DMF submissions for raw materials[25]. - The company has a total of 745 R&D personnel, including 144 with master's degrees and 45 with doctoral degrees[24]. - The global pipeline of new drugs reached 16,000 in 2019, reflecting a year-on-year growth of approximately 6%, supporting the rapid development of the CDMO business[22]. - The company has submitted 7 invention patent applications and received 5 invention patent grants in the first half of the year, with a total of 123 effective patents by the end of the reporting period[25]. Environmental and Social Responsibility - The company has invested in 12 sets of RTO waste gas treatment facilities, achieving a total organic waste gas treatment capacity of 350,000 m³/h[28]. - The company has implemented a three-year action plan for EHS, focusing on VOCs governance and ensuring the normal operation of pollution prevention facilities[28]. - The company has established a comprehensive emergency response plan for safety and environmental incidents, with all subsidiaries having set up EHS management organizations[58]. - The company has actively engaged in social responsibility initiatives, including charity activities and support for employees in need[62]. Financial Management - The company's financial expenses increased significantly by 356.11% due to exchange losses, compared to a gain in the previous year[32]. - The company aims to become a leading technology-driven pharmaceutical manufacturer in China, supported by its "344" quality management model[31]. - The company has established a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[31]. - The company has passed multiple international certifications, including WHO, FDA, and EU EDQM, enhancing its credibility in the global market[31]. Shareholder Information - The total share capital as of the last trading day before disclosure was 1,178,523,492 shares[12]. - The company has implemented an employee stock ownership plan, acquiring 32,664,016 shares, which represents 2.77% of the total share capital, for a total transaction amount of ¥260,658,847.68[49]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, amounting to 330,941,729 shares[90]. Compliance and Governance - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete financial conditions[138]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[136]. - The company has not faced any administrative penalties for environmental issues during the reporting period[59]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[65].